2. Signaling Pathways
  3. GPCR/G Protein
  4. Angiotensin Receptor
  5. Angiotensin Receptor Isoform
  6. Angiotensin Receptor Agonist

Angiotensin Receptor Agonist

Angiotensin Receptor Agonists (11):

Cat. No. Product Name Effect Purity
  • HY-15778
    AVE 0991
    		Agonist 99.91%
    AVE 0991 is a nonpeptide and orally active angiotensin-(1-7) receptor agonist with an IC50 of 21 nM.
  • HY-P0108
    Angiotensin II 5-valine
    		Agonist 99.35%
    Angiotensin II 5-valine is an agonist of angiotensin receptor.
  • HY-P2217
    Aclerastide
    		Agonist 99.62%
    Aclerastide (DSC-127) is an angiotensin receptor agonist. Aclerastide also is a peptide analog of angiotensin II. Aclerastide can be used for the research of tissue regeneration in diabetic ulcers.
  • HY-P1515A
    Angiotensin II (3-8), human TFA
    		Agonist 99.14%
    Angiotensin II (3-8), human (TFA) is a less effective agonist at the angiotensin AT1 receptor.
  • HY-15778A
    AVE 0991 sodium salt
    		Agonist 99.47%
    AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21 nM.
  • HY-112824
    L-162313
    		Agonist 98.51%
    L-162313 is a non-peptide angiotensin II AT1 and AT2 receptor agonist, with IC50 values of 1.1 and 2.0 nM for AT1 and AT2 receptor, respectively. L-162313 can be used for the research of vasoconstriction, aldosterone release, and cardiovascular growth.
  • HY-P2381
    Sar-Arg-Val-Tyr-Val-His-NH2
    		Agonist
    Sar-Arg-Val-Tyr-Val-His-NH2 is a Gq-biased agonists, exhibits 10-fold larger molecular efficacies at the AT1R-Gq fusion protein compared with the AT1R-βarr2 fusion protein.
  • HY-P1792A
    Angiotensin II (1-4), human TFA
    		Agonist
    Angiotensin II (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca2+ levels. Angiotensin II also acts at the Na+/H+ exchanger in the proximal tubules of the kidney.
  • HY-P1792
    Angiotensin II (1-4), human
    		Agonist
    Angiotensin II (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca2+ levels. Angiotensin II also acts at the Na+/H+ exchanger in the proximal tubules of the kidney.
  • HY-P1515
    Angiotensin II (3-8), human
    		Agonist
    Angiotensin II (3-8), human is a less effective agonist at the angiotensin AT1 receptor.
  • HY-100113R
    Buloxibutid (Standard)
    		Agonist
    Buloxibutid (AT2 receptor agonist C21) (Standard) is the analytical standard of Buloxibutid (HY-100113). This product is intended for research and analytical applications. Buloxibutid is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a Ki value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis.